Expression, structure, and function of androgen receptor in advanced prostatic carcinoma

Prostate

Volumn 35, Issue 1, 1998, Pages 63-70

  Culig, Zoran ^a   Hobisch, Alfred ^a   Hittmair, Anton ^b   Peterziel, Heike ^c   Cato, Andrew C B ^c   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

Androgen ablation therapy; Androgen receptor; Antiandrogens; Growth factors; Mutations; Prostate cancer progression; Second messengers

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; CYCLIC AMP; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HUMAN; HUMAN CELL; MALE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROGENS; GENE EXPRESSION; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 0031946389     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I     Document Type: Article

References (77)

1. Huggins C, Hodges CV: Studies on prostatic cancer: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
3. Chang C, Kokontis J, Liao S: Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 1988;85:7211-7215.
4. El Etreby MF, Habenicht UF, Louton T, Nishino Y, Schroder HG: Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats. Prostate 1987;11:361-375.
5. Kemppainen JA, Lane MV, Sar M, Wilson EM: Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. J Biol Chem 1992;267:968-974.
6. Diamond DA, Barrack ER: The relationship of androgen receptor levels to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines. J Urol 1984;132:821-827.
7. Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J: Establishment and characterization of seven Dunning rat prostatic cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-281.
8. Quarmby VE, Beckman WC Jr, Cooke DB, Lubahn DB, Joseph DR, Wilson EM, French FS: Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 1990;50:735-739.
9. Steiner MS, Barrack ER: Transforming growth factor-1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
10. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-5386.
11. Trapman J, Ris-Stalpers C, van der Korput JAGM, Kuiper GGJM, Faber PW, Romijn JC, Mulder E, Brinkmann AO: The androgen receptor: Functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. J Steroid Biochem Mol Biol 1990;37:837-842.
12. Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV, Bartsch G: DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993;22:11-22.
13. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
14. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
15. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostatic carcinoma cell line (DU-145). Int J Cancer 1978;21:274-281.
16. Kozlowski JM, Fidler IJ, Campbell D, Xu Z-L, Kaighn ME, Hart IR: Metastatic behavior of human cell lines grown in the nude mouse. Cancer Res 1984;44:3522-3529.
17. Gleave ME, Hsieh JT, Gao C, von Eschenbach A, Chung LWK: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51: 3753-3761.
18. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LWK: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52: 1598-1605.
19. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM: Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995;136:796-805.
20. Kokontis J, Takakura K, Hay N, Liao S: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994;54: 1566-1573.
21. Umekita Y, Hiipakka RA, Kokontis JM, Liao S: Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 1996;93: 11802-11807.
22. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK: Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996;93:15152-15157.
23. De Winter JA, Trapman J, Brinkmann AO, Boersma WJ, Mulder E, Schroeder FH, Claassen E, van der Kwast TH: Androgen receptor heterogeneity in human prostate carcinomas visualized by immunohistochemistry. J Pathol 1990;160:329-332.
24. Sadi MV, Walsh PC, Barrack ER: Immunohistochemical study of androgen receptors in metastatic prostate cancer-comparison of receptor content and response to hormonal therapy. Cancer 1991;67:3057-3064.
25. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CCJ, Mulder E, Boersma W, Trapman J: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991;48:189-193.
26. Sadi MV, Barrack ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer-heterogeneity as a predictor of response to hormonal therapy. Cancer 1993;71: 2574-2580.
27. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM: Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis. Cancer Res 1994;54:4096-4102.
28. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996;28:129-135.
29. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068-3072.
30. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398.
31. Kleinerman DI, Troncoso P, Pisters LL, Navone NM, Hsieh J-T, Logothetis CJ, Von Eschenbach AC, Sleddens HFBM, Van der Kwast TH, Brinkmann AO, Schroeder FH, Trapman J: Expression and structure of the androgen receptor in bone metastases of hormone refractory prostate cancer. J Urol 1996;155:626A (abst).
32. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinnen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 1995;9:401-406.
33. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56:3091-3102.
34. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP: Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-319.
35. 2-terminal and steroid-binding domains. J Biol Chem 1993;268:19004-19012.
36. Wong CI, Kelce WR, Sar M, Wilson EM: Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 1995;270:19998-20003.
37. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato ACB: Mutant androgen receptors in prostatic tumors distinguish between amino acid sequence requirements for transactivation and ligand binding. Int J Cancer 1995;63:544-550.
38. Harris SE, Rong Z, Harris MA, Lubahn DB: Androgen receptor in human prostate carcinoma LNCaP/Adep cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region. Program and Abstracts, 72nd Annual Meeting of the Endocrine Society, Atlanta, GA, p 93, 1990.
39. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992;89: 6319-6323.
40. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H: Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993;7:1541-1550.
41. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vihko P: Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 1995;80:3494-3500.
42. Evans BAJ, Harper ME, Daniells CE, Watts CE, Matenhelia S, Green J, Griffiths K: Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 1996;28:162-171.
43. Castagnaro M, Yandell D, Dockhorn-Dworniczak, Wolfe H, Poremba C: Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh Dtsch Ges Pathol 1993;77:119-123.
44. Tilley WD, Buchanan G, Hickey TE, Bentel JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-285.
45. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;17:534-540.
46. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E: Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992;31:2393-2399.
47. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ: Hormonal regulation of prostatespecific antigen (PSA) glycoprotein in the human adenocarcinoma cell line, LNCaP. Prostate 1992;21:63-73.
48. Kelly WK, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 1993;149:607-609.
49. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566-1572.
50. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatmens of "hormone-refractory" prostate cancer. J Natl Cancer Inst 1994;86:222-227.
51. Dawson NA, McLeod DG: Dramatic PSA decline in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome. J Urol 1995;153:1946-1947.
52. Small EJ, Carroll PR: Prostate-specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 1994;43:408-410.
53. Nieh PT: Withdrawal phenomenon with the antiandrogen Casodex. J Urol 1995;153:1070-1073.
54. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang D-Y, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-459.
55. Bubley G, Fenton M, Fertig A, DeWolf W, Shuster T, Balk S: The hormonal sensitivity of androgen receptor (AR) mutations derived from human tumors. Proc Am Assoc Cancer Res 1996;37: 1680 (abst).
56. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 1996;29:153-158.
57. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S: Frequent detection of codon 877 mutation in the advanced prostate cancer. Cancer Res 1994;54: 2861-2864.
58. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J: Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993;46:759-765.
59. 24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994;198:74-80.
60. Aronica SM, Katzenellenbogen BS: Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 1993;7:743-752.
61. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLahlan JA: Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 1993;7:992-998.
62. Krusekopf S, Chaucherau A, Milgrom E, Henderson D, Cato ACB: Cooperation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. J Steroid Biochem Mol Biol 1991;40:239-245.
63. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994;54:5474-5478.
64. Culig Z, Hobisch A, Radmayr C, Hittmair A, Cronauer MV, Bartsch G, Klocker H: Regulation of androgen receptor-mediated transcription in DU-145 cells in response to insulin-like growth factor-I, cyclic adenosine monophsphate, phorbol ester and retinoic acid. Proc Am Assoc Cancer Res 1995;36:271 (abst).
65. Nazareth LV, Weigel NL: Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996;271:19900-19907.
66. Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Zhang J, Bartsch G, Klocker H: Synergistic activation of androgen receptor by androgen and luteinizing hormone releasing hormone in prostatic carcinoma cells. Prostate 1997;32:106-114.
67. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Jänne OA: Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology 1994;135:1359-1366.
68. De Ruiter PE, Teuwen R, Trapman J, Dijkema R, Brinkmann AO: Synergism between androgens and protein kinase-C on androgen-regulated gene expression. Mol Cell Endocrinol 1995; 110:R1-6.
69. Reinikainen P, Palvimo JJ, Jänne OA: Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 1996; 137:4351-4357.
70. Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB: Androgen up-regulates epidermal growth factor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 1995;55:3197-3203.
71. Reiter E, Kecha O, Hennuy B, Lardinois S, Klug M, Bruyninx M, Closset J, Hennen G: Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology 1995;136:3338-3345.
72. Gupta C, Chandorkar A, Nguyen AP: Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation. Mol Cell Endocrinol 1996;123:89-95.
73. Nakhla AM, Rosner W: Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of SHBG. Endocrinology 1996;137:4126-4129.
74. Nakhla AM, Romas NA, Rosner W: Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. J Biol Chem 1997;272:6838-6841.
75. Fujimoto N, Katzenellenbogen BS: Alteration in the agonist/ antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence. Mol Endocrinol 1994;8: 296-304.
76. Sartorius CA, Tung L, Takimoto GS, Horwitz KB: Antagonistoccupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem 1993;268:9262-9266.
77. Nordeen SK, Bona BJ, Moyer ML: Latent agonistic activity of the steroid antagonist, RU 486, is unmasked in cells treated with activators of protein kinase A. Mol Endocrinol 1993;7:731-742.